An Investigation of the Safety and Efficacy of Elidel® 1% Cream in Atopic Disease Modification, Assessed in a 3-year Randomized Double-blind Vehicle Controlled Phase to Evaluate Effects on Atopic Dermatitis in Infants, and a 2-3 Year Openlabel Phase to Evaluate the Effect of Early Intervention Versus Delayed Intervention With Elidel® on the Incidence of Asthma in Children - Trial 2017-001765-25
Access comprehensive clinical trial information for 2017-001765-25 through Pure Global AI's free database. This phase not specified trial is sponsored by Novartis and is currently status unknown. The study focuses on Atopic Dermatitis.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
2017-001765-25
Trial Details
EU Clinical Trials Register • 2017-001765-25
An Investigation of the Safety and Efficacy of Elidel® 1% Cream in Atopic Disease Modification, Assessed in a 3-year Randomized Double-blind Vehicle Controlled Phase to Evaluate Effects on Atopic Dermatitis in Infants, and a 2-3 Year Openlabel Phase to Evaluate the Effect of Early Intervention Versus Delayed Intervention With Elidel® on the Incidence of Asthma in Children
Study Focus
Sponsor & Location
Novartis
Timeline & Enrollment
N/A
N/A
N/A
Primary Outcome
Efficacy: (Primary 1) AD disease control over 36 months
ICD-10 Classifications
Atopic dermatitis
Atopic dermatitis, unspecified
Other atopic dermatitis
Acute atopic conjunctivitis
Allergic contact dermatitis
Data Source
EU Clinical Trials Register
2017-001765-25
Non-Device Trial